Abstract
Current research in animal biotechnology targeting neurodegenerative diseases is not useful unless and until it has certain translational importance. Preclinical small and large animal models are used in understanding the pathogenesis of neurodegenerative diseases or disorders, and validating their therapeutic targets, but both have their own merits and demerits. For example, large animals are more resemble to humans as compared to small rodents, whether small animal models are more feasible for gene therapy in contrast to their large counterparts. The current book chapter briefly highlights the advancement of knowledge regarding the pathogenesis of neurodegenerative diseases/disorders and molecular mapping of the possible drug targets with translational impacts. Hence, data were searched through Pubmed, Medline, Toxline, Research Gate, and Google using numerous combinations of terms pertaining to different aspects in this regard, giving emphasis on several preclinical models.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
